Wecome Pharmaceutical Co Ltd Net Asset Quality Index
Wecome Pharmaceutical Co Ltd net asset quality index. Wecome Pharmaceutical Co Ltd (300878) has a Net Asset Quality Index of 69.2% as of September 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥1.49 Billion minus total liabilities of CN¥458.37 Million yields net assets of CN¥1.03 Billion. A higher index indicates a stronger, lower-leverage balance sheet. See 300878 net assets for net asset value and shareholders' equity analysis.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Wecome Pharmaceutical Co Ltd (2013–2024)
Net asset quality index of Wecome Pharmaceutical Co Ltd from 2013 to 2024. This chart shows how Wecome Pharmaceutical Co Ltd's Net Asset Quality Index has evolved across 12 annual periods from 2013 to 2024. As of September 2025, the index stands at 69.2%, representing net assets of CN¥1.03 Billion against total assets of CN¥1.49 Billion CNY. Check Wecome Pharmaceutical Co Ltd PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Wecome Pharmaceutical Co Ltd Net Asset Quality Index by Year (2013–2024)
Wecome Pharmaceutical Co Ltd net asset quality index by year from 2013 to 2024. The table below presents the year-by-year Net Asset Quality Index for Wecome Pharmaceutical Co Ltd from 2013 to 2024, covering 12 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see 300878 market cap.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 71.0% | CN¥1.17 Billion | CN¥1.65 Billion | CN¥478.50 Million | ▲ +2.3 pp |
| 2023 | 68.8% | CN¥1.41 Billion | CN¥2.05 Billion | CN¥639.23 Million | ▼ -5.0 pp |
| 2022 | 73.8% | CN¥1.41 Billion | CN¥1.91 Billion | CN¥502.25 Million | ▼ -9.5 pp |
| 2021 | 83.2% | CN¥1.41 Billion | CN¥1.69 Billion | CN¥284.28 Million | ▼ -1.8 pp |
| 2020 | 85.0% | CN¥1.38 Billion | CN¥1.63 Billion | CN¥244.39 Million | ▲ +25.6 pp |
| 2019 | 59.4% | CN¥519.84 Million | CN¥875.87 Million | CN¥356.02 Million | ▼ -2.1 pp |
| 2018 | 61.4% | CN¥393.83 Million | CN¥641.12 Million | CN¥247.29 Million | ▼ -2.4 pp |
| 2017 | 63.8% | CN¥306.05 Million | CN¥479.74 Million | CN¥173.68 Million | ▼ -3.1 pp |
| 2016 | 66.9% | CN¥210.90 Million | CN¥315.14 Million | CN¥104.25 Million | ▲ +8.3 pp |
| 2015 | 58.6% | CN¥130.04 Million | CN¥221.89 Million | CN¥91.84 Million | ▲ +13.4 pp |
| 2014 | 45.2% | CN¥78.22 Million | CN¥173.04 Million | CN¥94.82 Million | ▲ +13.1 pp |
| 2013 | 32.1% | CN¥34.35 Million | CN¥107.13 Million | CN¥72.78 Million | — |